| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥431M | ¥225M | +91.6% |
| Cost of Sales | ¥403M | ¥290M | +39.1% |
| SG&A Expenses | ¥218M | ¥204M | +6.7% |
| Operating Income | ¥-475M | ¥-531M | +10.5% |
| Non-operating Income | ¥396,000 | ¥2M | -82.2% |
| Non-operating Expenses | ¥18M | ¥16M | +11.2% |
| Ordinary Income | ¥-493M | ¥-545M | +9.5% |
| Profit Before Tax | ¥-554M | ¥-545M | -1.7% |
| Income Tax Expense | ¥1M | ¥1M | +0.0% |
| Net Income | ¥-555M | ¥-546M | -1.7% |
| Net Income Attributable to Owners | ¥-555M | ¥-545M | -1.8% |
| Total Comprehensive Income | ¥-555M | ¥-545M | -1.8% |
| Interest Expense | ¥655,000 | ¥546,000 | +20.0% |
| Basic EPS | ¥-1.89 | ¥-2.18 | +13.3% |
| Dividend Per Share | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥1.89B | ¥1.11B | +¥780M |
| Cash and Deposits | ¥1.68B | ¥834M | +¥841M |
| Accounts Receivable | ¥45M | ¥99M | ¥-54M |
| Non-current Assets | ¥50M | ¥50M | ¥0 |
| Total Assets | ¥1.94B | ¥1.16B | +¥780M |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥-525M | ¥-579M | +¥54M |
| Investing Cash Flow | ¥-61M | - | - |
| Financing Cash Flow | ¥1.43B | ¥1.15B | +¥278M |
| Free Cash Flow | ¥-586M | - | - |
| Item | Value |
|---|---|
| Net Profit Margin | -128.8% |
| Current Ratio | 862.6% |
| Quick Ratio | 862.6% |
| Debt-to-Equity Ratio | 0.18x |
| Interest Coverage Ratio | -725.19x |
| Effective Tax Rate | -0.2% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | +91.9% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 338.64M shares |
| Treasury Stock | 101 shares |
| Average Shares Outstanding | 294.27M shares |
| Book Value Per Share | ¥4.86 |
| Item | Amount |
|---|---|
| Year-End Dividend | ¥0.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| CancerPrecisionMedical | ¥430M | ¥-7M |
| ResearchAndDevelopmentOfPharmaceuticalProducts | ¥3M | ¥-284M |
| Item | Forecast |
|---|---|
| Dividend Per Share Forecast | ¥0.00 |
| Current Liabilities | ¥219M | ¥328M | ¥-109M |
| Non-current Liabilities | ¥71M | ¥98M | ¥-28M |
| Total Liabilities | ¥289M | ¥426M | ¥-137M |
| Total Equity | ¥1.65B | ¥729M | +¥917M |
| Capital Stock | ¥786M | ¥50M | +¥736M |
| Capital Surplus | ¥28.25B | ¥27.52B | +¥736M |
| Retained Earnings | ¥-27.46B | ¥-26.91B | ¥-555M |
| Treasury Stock | ¥-4,000 | ¥-4,000 | ¥0 |
| Owners' Equity | ¥1.57B | ¥658M | +¥917M |
| Working Capital | ¥1.67B | - | - |